Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Rhea-AI Summary

Decoy Therapeutics (NASDAQ: DCOY) announced on Feb 11, 2026 that it joined the Webull Corporate Connect Service platform to provide an additional communication channel for shareholders and investors. The company said the portal will distribute corporate news, earnings reports, product updates, presentations and notifications to improve transparency and engagement.

Market Reality Check

Price: $0.7260 Vol: Volume 444,841 vs 20-day ...

low vol

$0.7260 Last Close

Volume Volume 444,841 vs 20-day average 6,025,709 indicates subdued trading ahead of this update. low

Technical Shares at 0.748 are trading below the 200-day MA of 0.8, sitting 46.95% below the 52-week high and 21.63% above the 52-week low.

Peers on Argus

No peers from the Pharmaceutical Preparations sector appeared in the momentum sc...

No peers from the Pharmaceutical Preparations sector appeared in the momentum scanner, suggesting this communication-focused update is stock-specific rather than part of a broader sector move.

Historical Context

3 past events · Latest: Feb 05 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Investor presentation	Positive	-1.6%	Webull-hosted Corporate Connect webinar featuring CEO overview and pipeline highlights.
Feb 04	Investor segment	Positive	-7.6%	Virtual investor segment discussing Global Access Commitment Agreement with Gates Foundation.
Jan 13	Strategic agreement	Positive	+53.4%	Gates Foundation-backed Global Access Commitment Agreement for scalable antiviral platform.

Pattern Detected

Recent news has been generally positive, but price reactions skew mixed, with two negative moves following investor-focused events and one sharp gain on the Gates Foundation agreement.

Recent Company History

Over the past month, Decoy Therapeutics has issued several investor- and partnership-focused updates. On Jan 13, the company announced a Global Access Commitment Agreement with the Gates Foundation, which coincided with a 53.37% move higher. Subsequent Webull- and investor-related communications on Feb 4 and Feb 5 saw negative price reactions of -7.62% and -1.59%. Today’s Webull Corporate Connect participation continues this emphasis on investor outreach and visibility rather than new clinical or financial data.

Market Pulse Summary

This announcement adds Webull Corporate Connect as another investor-relations channel, aiming to imp...

Analysis

This announcement adds Webull Corporate Connect as another investor-relations channel, aiming to improve transparency and access to company updates. It follows recent communications around a Gates Foundation Global Access Commitment Agreement and investor webinars. With shares trading below the 0.8 200-day moving average and still 46.95% under the 52-week high, investors may monitor how enhanced outreach translates into engagement around future milestones and regulatory or clinical progress.

Key Terms

preclinical, peptide conjugate therapeutics

2 terms

preclinical medical

"a preclinical biopharmaceutical that is engineering the next generation"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

peptide conjugate therapeutics medical

"engineering the next generation of peptide conjugate therapeutics, today announced"

Peptide conjugate therapeutics are medicines made by attaching a short string of amino acids (a peptide) to another molecule—such as a drug, toxin or imaging agent—to guide it to specific cells or tissues. Like putting a GPS on a delivery truck, the peptide helps the active cargo find its target, which can increase effectiveness and reduce side effects; investors care because this can improve clinical success, differentiate a product and affect commercial value and development risk.

AI-generated analysis. Not financial advice.

-  Connect with the Company on Webull here

CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.

Decoy's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base. Through Webull, the Company will release notifications regarding corporate content, such as company news, earnings reports, product news, presentations and more.

"At Decoy Therapeutics, we are committed to clear and transparent communication with our shareholders. As we advance our programs and strategic initiatives, expanding awareness and engagement with the investor community is a critical part of our approach. Joining Webull Corporate Connect complements our existing investor relations efforts and social channels, providing an additional platform to share timely company updates and connect directly with our investors," commented Rick Pierce, Chief Executive Officer of Decoy Therapeutics.

To stay up to date on Decoy's recent developments on the Webull Corporate Connect Services Platform, current Webull users can follow DCOY from the app on their smartphone or table device. To download the app and register for your free Webull account, visit www.webull.com/trading-platforms.

Others can access the Company's information on Webull here.

About Webull Financial

Webull Corporation owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull's trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at https://www.webullcorp.com/

About Decoy Therapeutics, Inc.

Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.  The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk  that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.   

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-joins-webull-corporate-connect-service-platform-302684427.html

SOURCE Decoy Therapeutics, Inc

FAQ

What does Decoy Therapeutics joining Webull Corporate Connect mean for DCOY shareholders?

It provides shareholders an additional, direct channel for company updates and notifications. According to the company, the Webull portal will publish corporate news, earnings reports, product updates and presentations to improve transparency and investor engagement.

How can investors follow DCOY on the Webull app after the Feb 11, 2026 announcement?

Current Webull users can follow DCOY from the Webull smartphone or tablet app. According to the company, users should search for ticker DCOY in the app and follow the corporate connect portal to receive push notifications and updates.

Will Decoy Therapeutics publish earnings reports on Webull Corporate Connect?

Yes; Decoy indicated it will release earnings reports via its Webull portal among other corporate content. According to the company, investors can expect notifications about earnings releases, company news, product updates and presentation schedules on the platform.

Does joining Webull Corporate Connect change Decoy Therapeutics' regulatory filings or disclosure obligations?

No; joining Webull does not alter regulatory filing requirements or legal disclosure obligations. According to the company, Webull is an additional communication channel and does not replace formal filings with regulators or official press release distribution.

What types of corporate content will Decoy post to the Webull Corporate Connect portal for DCOY?

Decoy said it will post company news, earnings reports, product news, presentations and other notifications. According to the company, the portal is intended to share timely updates and help connect directly with shareholders and interested investors.

Will following DCOY on Webull provide real-time notifications of Decoy Therapeutics events and presentations?

Yes; the company said followers will receive notifications for events and presentations through the Webull portal. According to the company, the service aims to enhance engagement by delivering timely alerts on news, earnings, product updates and investor presentations.